Global Human Plasma-derived Hyperimmune Product Market Growth 2023-2029

Global Human Plasma-derived Hyperimmune Product Market Growth 2023-2029

The global Human Plasma-derived Hyperimmune Product market size is projected to grow from US$ 1826.4 million in 2022 to US$ 2815.8 million in 2029; it is expected to grow at a CAGR of 6.4% from 2023 to 2029.

United States market for Human Plasma-derived Hyperimmune Product is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Human Plasma-derived Hyperimmune Product is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Human Plasma-derived Hyperimmune Product is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Human Plasma-derived Hyperimmune Product players cover CSL Behring, Grifols, Biotest, Kedrion, CBPO, Emergent (Cangene), Kamada, CNBG and Hualan Bio, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.

LPI (LP Information)' newest research report, the “Human Plasma-derived Hyperimmune Product Industry Forecast” looks at past sales and reviews total world Human Plasma-derived Hyperimmune Product sales in 2022, providing a comprehensive analysis by region and market sector of projected Human Plasma-derived Hyperimmune Product sales for 2023 through 2029. With Human Plasma-derived Hyperimmune Product sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Human Plasma-derived Hyperimmune Product industry.

This Insight Report provides a comprehensive analysis of the global Human Plasma-derived Hyperimmune Product landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Human Plasma-derived Hyperimmune Product portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Human Plasma-derived Hyperimmune Product market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Human Plasma-derived Hyperimmune Product and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Human Plasma-derived Hyperimmune Product.

This report presents a comprehensive overview, market shares, and growth opportunities of Human Plasma-derived Hyperimmune Product market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type
Hepatitis B Immunoglobulins
Rabies Immunoglobulins
Tetanus Immunoglobulins
Rho(D) Immunoglobulins
Other

Segmentation by application
Government Institution
Private Sector
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
CSL Behring
Grifols
Biotest
Kedrion
CBPO
Emergent (Cangene)
Kamada
CNBG
Hualan Bio
Shanghai RAAS
Sichuan Yuanda Shuyang
ADMA Biologics

Key Questions Addressed in this Report

What is the 10-year outlook for the global Human Plasma-derived Hyperimmune Product market?

What factors are driving Human Plasma-derived Hyperimmune Product market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Human Plasma-derived Hyperimmune Product market opportunities vary by end market size?

How does Human Plasma-derived Hyperimmune Product break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.